Stem Cell Tech Firm VistaGen Goes Public via Reverse Merger
By Jennifer Boggs
Wednesday, May 18, 2011
The latest firm to opt for a reverse merger rather than the more traditional initial public offering, VistaGen Therapeutics Inc. inked a deal to merge with Excaliber Enterprises Ltd., a public shell listed on the Over-the-Counter Bulletin Board.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.